Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

Item

http://www.wikidata.org/entity/Q30434934

Q30434934

about

Recent progress in pancreatic cancer Improving the efficacy of chemoradiation with targeted agents Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Radiotherapy and "new" drugs-new side effects?The pancreas cancer microenvironment Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials.Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence.Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.Interaction of radiation therapy with molecular targeted agents S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis.Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma New targeted therapies in pancreatic cancer.Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience.Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review New paradigms and future challenges in radiation oncology: an update of biological targets and technology.Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.Microenvironment and radiation therapy Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer.To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.Prospective review of radiotherapy trials through implementation of standardized multicentre workflow and IT infrastructure Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.Emerging antibodies for the treatment of pancreatic cancer.Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort.Radiotherapy in combination with vascular-targeted therapies.Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection.Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial.

P2860

Q24626346-44CDA381-1DC8-4D8D-9C9F-1756E28400E5 Q26850193-68EFAE87-9C2D-4E40-9EA3-E2B98B08E015 Q26853171-DC4864FD-0650-498E-82D6-D774D6BD7BF5 Q26861498-6E781538-5AAC-454E-B09A-D68258C9298C Q27026705-2004A821-1850-4041-99C2-BAF988AC28D3 Q28552089-8A0367C3-FCEB-4824-B8FB-362DCE5B52F1 Q30411811-8912B752-4828-407E-A8FC-81FC30DEF507 Q30424980-62A9D39C-D8EE-4A6F-9305-F3157D6BF57F Q33400984-B1E346CA-3842-40A4-A26C-93D7517DB178 Q33680243-839652DA-4119-411A-8D05-61180FBBBAF3 Q33802617-91735F02-A2E7-44C2-8C5D-D0DB04E33C93 Q33951007-8D2660BF-608D-4865-ACF4-DCFD6029AA64 Q34124285-8999315D-F307-45A7-B8DA-0396D99428A9 Q34326711-51546362-512A-4D89-854D-B194A50D787C Q34342960-05CA082F-FFA4-48FF-BF79-5B1A131DFC10 Q34537580-B7C2BCDB-7162-4F03-907A-4766BA429EAD Q34635042-F28ED831-6502-4190-B542-21F27158331F Q35050606-597DB548-0DE8-4DA9-8FD0-990396C28F3E Q35567270-8E862F26-52BE-4FBE-8256-4F9382AD5698 Q35651453-1936FF34-0909-4721-8393-B6A90997391E Q35820403-8872C043-A01A-4FF7-A93B-F99D0DDB151E Q36033068-F56D88BC-9CDE-4D93-83E0-BDE41D5AE307 Q36381222-32E76A34-3B60-45E1-BDAC-58F6FA893604 Q36544488-6E6EDBDD-A735-492D-A5FD-D05269E96016 Q37102447-A3856AD4-ADB2-4AD9-AF16-5A26BCA7BC5A Q37110377-EF0ED40F-A27C-482C-93DA-7A3156A33AE2 Q37160539-FC60885E-7D2A-4835-9C45-66056AA22C16 Q37401414-9A73DD82-353C-4C7B-822A-E6D138099E75 Q38091084-7233D924-25ED-4A64-A521-A74F427D3F12 Q38096479-DD7F954A-2CE3-43C3-8A45-55323C3E8DEC Q38105006-E5D356E5-C168-4A68-B289-CA6467D4D0F4 Q38380009-83BBDE9C-03AA-4B79-81E5-092E67EBE830 Q38684978-A81673DF-BF3D-48CD-A70F-5E25BEF126DB Q39158427-3C96C6A4-FE1A-4CBD-9E84-F589838795D6 Q39376002-D8C9B625-A95B-4501-AD3D-083D02789692 Q42203737-4C814F8D-347B-4985-84FD-C440D7CCD8D5 Q42700802-FCE29042-0A98-49FD-A7CA-D3403FD1F48D Q43615997-1D0ED3EE-5E33-4A4A-A9D6-95EA53BF0229 Q44650366-5599F3B7-C819-40FF-88AE-0EAFD09224C2 Q48149165-E9BB4ABE-B7FB-4015-984C-DDB9F3E79DB5

P2860

Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

Item

http://www.wikidata.org/entity/Q30434934

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu